Achieving cost effective, scalable high-titer AAV production
Aug
24
2024
Upcoming webinar

Achieving cost effective, scalable high-titer AAV production

Saturday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Sponsor
Achieving cost effective, scalable high-titer AAV production

Adeno-associated virus (AAV) is rapidly becoming the go-to biological delivery method for the latest gene therapy breakthroughs. AAV has an efficacy and safety profile that makes it an ideal therapeutic vector—already part of several high-profile drug approvals in both the US and Europe. Yet, with this intensified interest in AAV therapies comes the need to scale-up viral production methods. As such, it’s imperative that successful viral production delivers high titers cost effectively and is scalable. During this webinar session, our presenter will highlight a scalable, high-titer, simplified AAV production in the AAV-MAX helper-free AAV Production System.

  • Methods to increase AAV titers, reducing overall production costs
  • Scalable protocols for suspension systems, from shake flask to bioreactor scale
  • Streamlining a helper virus–free triple transfection protocol to simplify workflow
Chao Yan Liu
Chao Yan Liu
Senior Manager, R&D, Cell Biology Thermo Fisher Scientific
Chao Yan Liu is a R&D Senior Manager, Cell Biology at the Life Sciences Solutions Group based in Frederick (MD - USA). Chao Yan Liu received the M.D. degree from the Hebei Medical University (Hebei, China) and the Master degree in Pathology from the Academy of Medical Sciences in Beijing, China. She got her post-doctoral training at Blood Research Institute, Medical school of Wisconsin and then became research assistant professor at the University of Buffalo, New York. After being very active for more than ten years in academic research in the field of cellular biology and immunology, in 2005 she joined the Research and Development department of the former Life Technologies. She has made great contributions to more than ten of the GIBCO® brand Cell Culture Essential products including AlgiMatrix™ 3D Culture System, OpTmizer™ CTS™ T-Cell Expansion SFM, TrypLE™ Select Enzyme, ES Cell Qualified FBS, GlutaMAX™ media supplement, FreeStyle™ F17 Expression Medium and CD FortiCHO™ Medium. She has extensive experiences in mammalian cell culture, serum and protein free, chemical defined medium formulation, as well as protein expression. She served as leading scientist to develop two novel transient transfection systems, Expi293™ and ExpiCHO™ Expression Systems. In the past two years, she and her team focused on both protein expression and viral production system development.
Christine Le Bec
Christine Le Bec
Head, CMC, Gene Therapy at Sensorion

Christine Le Bec joined Sensorion Pharma in early 2020 as Head of CMC Gene Therapy. She is responsible for all CMC activities, including pre-clinical development, CMC transfer to CMOS, manufacturing and supplying of Phase 1 and 2 clinical trails. Before joining Sensorion Pharma, she worked for more than 20 years at Genethon in the field of Gene Therapy vectors (AAV, Lentivirus, Baculovirus) for rare diseases. She has a strong expertise in the development, qualification, validation of analytical methods for product characterization, release testing of gene therapy products and in stability studies. She has also a solid knowledge of International regulations and reviewing CMC documents for clinical trial applications.

in 42
Days

SPEAKERS

Chao Yan Liu
Chao Yan Liu
Senior Manager, R&D, Cell Biology Thermo Fisher Scientific
Christine Le Bec
Christine Le Bec
Head, CMC, Gene Therapy at Sensorion